NCT03845868

Brief Summary

Tongji-Ezhou study (TJEZ) is a prospective cohort study launched at 2013 in EZhou city, Hubei province, with the goal of recruiting and assessing 10,000 individuals and then following them for at least 2 decades. In addition, blood samples would be collected every 3-5 years among 6000 of them to investigate the nutritional biomarkers and potential determinants of chronic diseases such as obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 16, 2013

Completed
5.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2019

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

February 14, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 19, 2019

Completed
6.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

February 19, 2019

Status Verified

February 1, 2019

Enrollment Period

5.8 years

First QC Date

February 14, 2019

Last Update Submit

February 16, 2019

Conditions

Outcome Measures

Primary Outcomes (4)

  • Incidence of diabetes

    Type 2 diabetes was diagnosed when FPG ≥ 7.0 mmol/L and/or OGTT2h ≥ 11.1 mmol/L, or using diabetic medication (self-report).

    5 years

  • Incidence of metabolic syndrome

    Metabolic syndrome is defined as using the updated National Cholesterol Education Program/Adult Treatment Panel III criteria for Asian Americans. These criteria require three or more of the following components: (1) central obesity (waist circumference of ≥90 cm for men or ≥80 cm for women), (2) triglycerides of ≥1.7 mmol/L, (3) HDL-C of \<1.03 mmol/L for men or \<1.30 mmol/L for women, (4) blood pressure of ≥130/85 mmHg or on medication for hypertension, and (5) fasting glucose of ≥5.6 mmol/L.

    5 years

  • Diabetic complications

    Development of diabetic complications

    mean follow up of 10 years

  • Incidence of cardiovascular diseases

    Cardiovascular death, stroke, myocardial infarction, heart failure

    mean follow up of 10 years

Study Arms (2)

Egang hospital physical examination center

Other: Dietary and environmental exposure (Observational study)

Ezhou CDC physical examination center

Other: Dietary and environmental exposure (Observational study)

Interventions

Egang hospital physical examination centerEzhou CDC physical examination center

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Samples were collected at two medical centrals (retired employees at Egang hospital and working employees at Ezhou CDC). The Retirement Office of Egang hospital and Health checkup center of CDC provided a list of the individuals and invited them to participant in our study.

You may qualify if:

  • (i) permanent residence in Ezhou district (minimum of 9 months); (ii) written informed consent; (iii) age ≥ 20 years old at the time of enrolling in the study.

You may not qualify if:

  • (i) with chemotherapy or radiotherapy for cancer and other severe diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

RECRUITING

Related Publications (1)

  • Sun T, Deng Y, Geng X, Fang Q, Li X, Chen L, Zhan M, Li D, Zhu K, Li H, Liu L. Plasma Alkylresorcinol Metabolite, a Biomarker for Whole-Grain Intake, Is Inversely Associated with Risk of Nonalcoholic Fatty Liver Disease in a Case-Control Study of Chinese Adults. J Nutr. 2022 Apr 1;152(4):1052-1058. doi: 10.1093/jn/nxab404.

Biospecimen

Retention: SAMPLES WITH DNA

Blood, urine, and DNA were collected by clinicians during the morning after the examinees. Blood samples (5 ml) are collected with ethylenediamine tetra acetic acid anticoagulant tube from peripheral vessels. Plasma, buffy coat, and red blood cell layer are separated. The samples are stored at -80°C for future analyses. All bio-samples will be tracked through an electronic database.

MeSH Terms

Conditions

Diabetes MellitusCardiovascular DiseasesObesityMetabolic SyndromeNutritional and Metabolic Diseases

Interventions

DietEnvironmental ExposureObservation

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesEndocrine System DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsInsulin ResistanceHyperinsulinism

Intervention Hierarchy (Ancestors)

Nutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological PhenomenaEnvironmental PollutionPublic HealthEnvironment and Public HealthMethodsInvestigative Techniques

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Vice dean of School of Public Health, Tongji Medical College

Study Record Dates

First Submitted

February 14, 2019

First Posted

February 19, 2019

Study Start

April 16, 2013

Primary Completion

January 31, 2019

Study Completion

December 31, 2025

Last Updated

February 19, 2019

Record last verified: 2019-02

Locations